A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects With Stage V Chronic Kidney Disease on Hemodialysis
收藏DataCite Commons2025-01-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002952/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
提供机构：
Vivli
创建时间：
2018-10-27
